An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.
Tiffany P. Avery
No relevant relationships to disclose
Adam C. Berger
No relevant relationships to disclose
Albert J. Kovatich
No relevant relationships to disclose
Hallgeir Rui
No relevant relationships to disclose
Terry Hyslop
No relevant relationships to disclose
Edith P. Mitchell
No relevant relationships to disclose